NCT00398515View on ClinicalTrials.gov

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2012

Conditions
Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

lenalidomide

Given orally

DRUG

temsirolimus

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00398515 - Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | Biotech Hunter | Biotech Hunter